|
BP15961
|
Carboxyamidotriazole Orotate
|
|
|
|
|
Carboxyamidotriazole Orotate is a cytostatic inhibitor of nonvoltage-operated calcium channels and calcium channel-mediated signaling pathways. Carboxyamidotriazole Orotate (L-651582 Orotate) is the orotate salt form of Carboxyamidotriazole (CAI), an orally bioavailable signal transduction inhibitor. Carboxyamidotriazole Orotate shows anti-tumor, anti-inflammatory and antiangiogenic effects.
|
|
BP15962
|
Cariporide
|
|
|
|
|
Cariporide (HOE-642), an effective NHE1 inhibitor, has inhibitory effects on the degranulation of human platelets, the formation of platelet-leukocyte-aggregates, and the activation of the GPIIb/IIIa receptor (PAC-1).
|
|
BP15963
|
Caroverine hydrochloride
|
|
|
|
|
Caroverine HCL is a potent, competitive and reversible antagonist of NMDA and AMPA glutamate receptor. It is also an antioxidant and calcium-blocking agent that exhibits vasorelaxant action, and can be used for the research of inner ear tinnitus.
|
|
BP15964
|
Cav 2.2 blocker 1
|
|
|
|
|
Cav 2.2 blocker 1 is an N-type calcium channel (Cav 2.2; IC50: 1 nM) blocker for the treatment of pain.
|
|
BP15965
|
CBS9106
|
|
|
|
|
CBS9106 (SL-801) is a reversible oral inhibitor of CRM1 with CRM1 degrading and antitumor activities. CBS9106 arrests the cell cycle and inducing apoptosis in a time- and dose-dependent manner for a broad spectrum of cancer cells.
|
|
BP15966
|
CCR4 antagonist 2
|
|
|
|
|
CCR4 antagonist 2 (Compound 31) is a novel potent, orally bioavailable small molecule antagonists of CC chemokine receptor 4 (CCR4) that inhibits Treg trafficking into the Tumor Microenvironment without suppressing the number of Treg in healthy tissues. CCR4 antagonist 2 (Compound 31) exhibits IC50 values of Ca2+flux and (chemotaxis) CTX are 40 nM and 70 nM, respectively.
|
|
BP15967
|
CDN1163
|
|
|
|
|
CDN1163 is a small molecule activator of sarco/endoplasmic reticulum Ca2+-ATPase (SERCA).
|
|
BP15968
|
CGP 35348
|
|
|
|
|
CGP 35348 is a selective antagonist of GABAB receptor (EC50 = 34 μM). CGP 35348 can be used in studies of neuromuscular coordination and spatial learning after neonatal brain damage in albino mice.
|
|
BP15969
|
Chlorahololide C
|
|
|
|
|
Chlorahololide C is a potent and selective potassium channel blocker, it exerts potent and selective inhibition on the delayed rectifier (I(K)) K(+) current with the IC(50) value of 3.6 +/- 10.1 mu M.
|
|
BP15970
|
Chloroprocaine hydrochloride
|
|
|
|
|
Chloroprocaine HCl is a local anesthetic during surgical procedures.
|
|
BP15971
|
Chlorzoxazone
|
|
|
|
|
Chlorzoxazone is a Muscle Relaxant. The physiologic effect of chlorzoxazone is by means of Centrally-mediated Muscle Relaxation.
|
|
BP15972
|
Cilnidipine
|
|
|
|
|
Cilnidipine(FRC8653) is a dual L- and N-type calcium channel blocker and displays antihypertensive, sympatholytic and neuroprotective activity.
|
|
BP15973
|
Cinacalcet metabolite M4
|
|
|
|
|
Cinacalcet metabolite M4 is a metabolite of Cinacalcet. Cinacalcet is an allosteric agonist of Ca receptor.
|
|
BP15974
|
Cinnamyl caffeate
|
|
|
|
|
Cinnamyl caffeate has cardiovascular protective effects, it can increase H9c2 cellular antioxidant potential, decrease intracellular calcium ion ([Ca2+]i) level, and prevent cell apoptosis; it possesses potent antiproliferative activity with the EC(50) value of 0.114 microM, toward colon 26-L5 carcinoma. Cinnamyl caffeate possesses potent NO inhibitory activity with the IC(50) value of 9.53 microM.
|
|
BP15975
|
cis-PDA
|
|
|
|
|
cis-PDA is a general ionotropic receptor antagonist. cis-PDA acts by blocking NMDA, AMPA, and kainate-mediated responses.
|
|
BP15976
|
Clevidipine
|
|
|
|
|
Clevidipine is a dihydropyridine L-type calcium channel blocker that is selective for vascular smooth muscle and is indicated for blood pressure reduction when oral therapy is not an option.
|
|
BP15977
|
Clorsulon
|
|
|
|
|
Clorsulon is utilized for the treatment of Fasciola hepatica infections in calves and sheep.
|
|
BP15978
|
CLP257
|
|
|
|
|
CLP257 is a selective K+-Cl− cotransporter KCC2 activator (EC50: 616 nM) and it is inactive against NKCC1, GABAA receptors, KCC1, KCC3 or KCC4. CLP257 alleviates hypersensitivity in rats with neuropathic painc and it also modulates plasmalemmal KCC2 protein turnover post-translationally. CLP257 restores impaired Cl− transport in neurons with diminished KCC2 activity.
|
|
BP15979
|
CLP290
|
|
|
|
|
CLP290 is an activator of the neuron-specific K+-Cl cotransporter KCC2 and displays potential for the treatment of a wide range of neurological and psychiatric indications.
|
|
BP15980
|
CNQX
|
|
|
|
|
CNQX is a competitive, non-NMDA glutamate receptor antagonist (IC50s = 0.3 and 1.5 μM for AMPA and kainate receptors, respectively)
|
